STOCK TITAN

Deciphera Pharmaceuticals Inc - DCPH STOCK NEWS

Welcome to our dedicated news page for Deciphera Pharmaceuticals (Ticker: DCPH), a resource for investors and traders seeking the latest updates and insights on Deciphera Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Deciphera Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Deciphera Pharmaceuticals's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
offering
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.55%
Tags
offering
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.32%
Tags
offering
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.96%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.75%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.4%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
conferences
Deciphera Pharmaceuticals Inc

Nasdaq:DCPH

DCPH Rankings

DCPH Stock Data

1.23B
41.33M
30.49%
73.38%
6.82%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Waltham

About DCPH

deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.